Analyst Confidence Soars for Akero Therapeutics Following Key Presentations

Investor attention is firmly fixed on Akero Therapeutics today, fueled by a wave of positive analyst commentary and a significant corporate presentation delivered at yesterday’s Morgan Stanley Healthcare Conference. The company’s shares concluded the previous trading session at $44.57.

Major Firms Issue Bullish Outlooks

The investment thesis for Akero received substantial backing from two prominent research institutions. H.C. Wainwright initiated coverage on the biopharmaceutical company, assigning a “Buy” recommendation alongside a $72 price target. An even more optimistic stance was taken by Morgan Stanley, which reaffirmed an “Overweight” rating and established a street-high price objective of $84.

The company’s strategic direction was further highlighted by CEO Andrew Cheng during the recent conference. His presentation detailed the promising Phase 3 program targeting the MASH market, which encompasses the SYNCHRONY Histology, SYNCHRONY Outcomes, and SYNCHRONY Real-World trials.

Clinical Data Fuels Competitive Edge

A pivotal factor behind the analyst enthusiasm is Akero’s strengthened competitive position. This follows Novo Nordisk’s decision to exit MASH drug development after encountering setbacks in its own Phase 2 studies.

Should investors sell immediately? Or is it worth buying Akero Therapeutics?

Akero’s drug candidate, efruxifermin (EFX), has demonstrated compelling results. Data from the Phase 2b SYMMETRY study, published in the New England Journal of Medicine in May 2025, showed the drug’s ability to reverse liver cirrhosis in patients. This breakthrough positions EFX as a potential first-in-class therapy for advanced MASH.

• Morgan Stanley Price Target: $84
• H.C. Wainwright Price Target: $72
• Current Share Price: $44.57
• Cash Runway: Funded into 2028

Upcoming Catalysts on the Horizon

The path forward is marked by clearly defined clinical milestones. Investors can anticipate initial results from the SYNCHRONY Real-World study in the first half of 2026. This will be followed by pivotal data readouts from the SYNCHRONY Histology study, expected in the first half of 2027.

The analyst consensus continues to reflect a “Strong Buy” sentiment, with an average price target of $80.38. The combination of robust financial backing, concrete clinical progress, and overwhelming analyst support currently paints a compelling picture for the company’s future.